Develops and commercializes biopharmaceuticals.
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2026 | BIOMARIN PHARMACEUTICAL INC. |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | $340,000 | |
| 2026 | BIOMARIN PHARMACEUTICAL INC. |
2nd Quarter (Apr 1 - June 30) AMENDED |
— | $340,000 | |
| 2026 | BIOMARIN PHARMACEUTICAL INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $340,000 | |
| 2026 | BIOMARIN PHARMACEUTICAL INC. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $530,000 | |
| 2025 | BIOMARIN PHARMACEUTICAL INC. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $390,000 | |
| 2025 | BIOMARIN PHARMACEUTICAL INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $270,000 | |
| 2025 | BIOMARIN PHARMACEUTICAL INC. |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $270,000 | |
| 2025 | BIOMARIN PHARMACEUTICAL INC. |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $390,000 | |
| 2024 | BIOMARIN PHARMACEUTICAL INC. |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $490,000 | |
| 2024 | BIOMARIN PHARMACEUTICAL INC. |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $240,000 |
| Client | Filings | Total Income |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | 57 | — |
| Name | Disclosed Prior Position |
|---|---|
| TERICKE BLANCHARD | NONE |
| JOHN EDWARD GREISSING | N/A |
| KATHRYN LOWELL | N/A |
| DANIEL MAYNE | SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG… |